The combined therapy simultaneously blocks the EGFR/VEGF pathway and downregulates signaling pathways at multiple sites, exhibiting synergistic anti-tumor activity and delaying the occurrence of TKI resistance. The gene discussed is EGFR; the disease is neoplasm.